Pear Therapeutics Obtains First Medicaid Coverage For PDTs
Executive Summary
Massachusetts’ Medicaid program will cover reSET and reSET-O prescription digital therapeutics for the treatment of substance abuse disorder and opioid use disorder.
You may also be interested in...
PDT Company Better Therapeutics Ready To Go Public With SPAC Deal
Better Therapeutics is developing prescription digital therapeutics for behavioral therapy to address the root causes of cardiometabolic disease.
Exec Chat: Pear Therapeutics’ CEO Charts Future For Digital Therapeutics Following SPAC Deal
Pear has commercialized FDA-cleared prescription digital therapeutics for substance abuse disorder, opioid use disorder and chronic insomnia and has 14 more in development. CEO Corey McCann explained Pear’s vision for how PDTs can transform health care.
Point Of Care Diagnostics Market Projected To Continue Rapid Growth
A new report from Informa's Meddevicetracker highlights strong projected growth in the market, explaining the underlying reasons why.